EUVIMEDEUVIMED entdecken
Crossref

Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series

Gráinne Marron iD, Niklesh Warrier, Kelvin Chan, Bradley Augustson

British Journal of Haematology · 2026-06 · 208 (6) · 2265-2268

DOI: 10.1111/bjh.70510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 29.04.2026. Verfasst von Gráinne Marron und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sir Charles Gairdner Hospital, Perth, Western Australia, Australia. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

antibodybispecifichaematologymyelomarenal failure

Autor:innen und Institutionen

  • Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.

ORCID-Profile: Gráinne Marron

Zitieren

APA

Marron, G., Warrier, N., Chan, K., & Augustson, B. (2026). Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series. British Journal of Haematology, 208(6), 2265-2268. https://doi.org/10.1111/bjh.70510

Vancouver

Marron G, Warrier N, Chan K, Augustson B. Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series. British Journal of Haematology. 2026;208(6):2265-2268. doi:10.1111/bjh.70510

BibTeX
@article{Marron2026,
  author = {Marron, Gráinne and Warrier, Niklesh and Chan, Kelvin and Augustson, Bradley},
  title = {Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {6},
  pages = {2265--2268},
  doi = {10.1111/bjh.70510}
}
Kostenlos starten →